GlassScriptPhysician profile
Jeremy A Ross
NPI 1013250455
$520,429.88
in general payments reported to CMS, 2019-2025
43 companies · $173K in 2025
The $173K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,886 · 2021: $5,629 · 2022: $54K · 2023: $136K · 2024: $149K · 2025: $173K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $361K · Travel and Lodging: $49K · Consulting Fee: $38K · Food and Beverage: $7,669 · Honoraria: $2,800 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $360,810.73 |
| Travel and Lodging | $49,339.84 |
| Consulting Fee | $37,805.50 |
| Food and Beverage | $7,668.60 |
| Honoraria | $2,800.00 |
| Education | $106.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $209,308.40 | 2021-2025 | Opdivo, Augtyro, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $208,240.08 | 2021-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $50,334.10 | 2023-2025 | Enhertu, Truqap, Calquence |
| Genzyme Corporation | $21,479.15 | 2021-2024 | |
| Glaxosmithkline, LLC. | $8,346.68 | 2022-2024 | Trelegy Ellipta |
| Pfizer INC. | $5,333.83 | 2021-2025 | |
| Kite Pharma, INC. | $4,796.54 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $2,817.93 | 2024-2025 | Libtayo |
| Novocure INC. | $2,600.00 | 2024 | Optune Lua (Novottf-200t) |
| Karyopharm Therapeutics INC. | $1,967.94 | 2020-2025 | Xpovio |
| Janssen Biotech, INC. | $1,800.21 | 2023-2025 | Erleada, Akeega, Imbruvica |
| Daiichi Sankyo INC. | $848.81 | 2021-2025 | Enhertu |
| Novo Nordisk INC | $218.99 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $196.60 | 2022-2023 | Lumakras |
| Abbvie INC. | $188.48 | 2024-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.